Literature DB >> 2620462

Serum growth hormone binding protein activity in healthy neonates, children and young adults: correlation with age, height and weight.

A Silbergeld1, L Lazar, B Erster, R Keret, R Tepper, Z Laron.   

Abstract

Serum growth hormone binding protein (GHBP) activity was estimated in healthy neonates (n = 6), children and adolescents (n = 97) and young adults (n = 19). GHBP activity was measured by incubating 125I-hGH (human growth hormone) (approximately 25,000 c.p.m.) with serum (100 microliters) in the presence and in the absence of excess unlabelled hGH, followed by separation of specifically bound 125I-hGHBP complexes from free 125I-hGH by gel filtration on Ultrogel AcA44 minicolumns. The results are expressed as the percentage specific binding relative to an adult reference serum (%RSB), after correction for endogenous hGH of the unknown serum. The between-assay coefficients of variation for two sera of %RSB activity of 51.2 and 115.4% were 6.0 and 7.0% respectively. In neonates, low values of serum GHBP were found (%RSB = 27.1 +/- 5.0 SEM) followed by a major rise during the first 6 years of life to a mean value (%RSB = 68.3 +/- 4.1 SEM) which more than doubled that of neonates. Thereafter, values rose progressively throughout childhood and puberty to reach maximum values in young adults (%RSB = 95.0 +/- 3.1 SEM). A novel observation was that serum GHBP activity correlated significantly with height standard deviation score (SDS) (males: r = 0.77, P less than 0.001; females: r = 0.56, P = 0.01) and weight SDS (P less than 0.001) for both sexes before puberty. During puberty GHBP correlated only with weight SDS in males (r = 0.60, P less than 0.01). In all age groups studied, no correlation could be found between serum GHBP and height velocity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2620462     DOI: 10.1111/j.1365-2265.1989.tb01253.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Growth in patients with isolated gonadotrophin deficiency.

Authors:  Z Dickerman; A Cohen; Z Laron
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

Review 2.  Somatomedin-1 (insulin-like growth factor-I) in clinical use. Facts and potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

3.  Developmental pattern of fetal growth hormone, insulin-like growth factor I, growth hormone binding protein and insulin-like growth factor binding protein-3.

Authors:  P Pirazzoli; E Cacciari; R De Iasio; M C Pittalis; P Dallacasa; S Zucchini; S Gualandi; S Salardi; C David; S Boschi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

Review 4.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

5.  Enhanced expression of mRNA for insulin-like growth factor-1 in post-burn hypertrophic scar tissue and its fibrogenic role by dermal fibroblasts.

Authors:  A Ghahary; Y J Shen; B Nedelec; P G Scott; E E Tredget
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

6.  Circulating levels of growth hormone, insulin-like growth factor-I and prolactin in normal, growth retarded and anencephalic human fetuses.

Authors:  M Arosio; D Cortelazzi; L Persani; E Palmieri; G Casati; A M Baggiani; G Gambino; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

7.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

8.  Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type 1 (insulin-dependent) diabetes mellitus.

Authors:  G Massa; L Dooms; R Bouillon; M Vanderschueren-Lodeweyckx
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

9.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Growth hormone binding protein activity in obese children.

Authors:  S Seminara; A Filpo; F La Cauza; A Faedda; A Miola; S Pellizzone; M Casati; S Loche
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.